Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

NCT06649656 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. as lead sponsor.

NCT NCT06649656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Lead sponsor
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2024
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancers